A detailed history of Canandaigua National Corp transactions in Abb Vie Inc. stock. As of the latest transaction made, Canandaigua National Corp holds 29,149 shares of ABBV stock, worth $5.25 Million. This represents 0.8% of its overall portfolio holdings.

Number of Shares
29,149
Previous 29,778 2.11%
Holding current value
$5.25 Million
Previous $4 Million 17.86%
% of portfolio
0.8%
Previous 0.71%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 07, 2023

SELL
$138.31 - $165.87 $86,996 - $104,332
-629 Reduced 2.11%
29,149 $4.71 Million
Q3 2022

Oct 05, 2022

SELL
$134.21 - $153.93 $22,010 - $25,244
-164 Reduced 0.55%
29,778 $4 Million
Q2 2022

Jul 05, 2022

SELL
$137.62 - $174.96 $37,295 - $47,414
-271 Reduced 0.9%
29,942 $4.59 Million
Q1 2022

May 09, 2022

SELL
$131.98 - $163.75 $189,655 - $235,308
-1,437 Reduced 4.54%
30,213 $4.9 Million
Q4 2021

Jan 04, 2022

SELL
$107.43 - $135.93 $38,782 - $49,070
-361 Reduced 1.13%
31,650 $4.29 Million
Q3 2021

Oct 04, 2021

BUY
$106.4 - $120.78 $259,084 - $294,099
2,435 Added 8.23%
32,011 $3.45 Million
Q2 2021

Jul 06, 2021

BUY
$105.21 - $117.21 $1,472 - $1,640
14 Added 0.05%
29,576 $3.33 Million
Q1 2021

Apr 05, 2021

SELL
$102.3 - $112.62 $44,091 - $48,539
-431 Reduced 1.44%
29,562 $3.2 Million
Q4 2020

Feb 11, 2021

BUY
$80.49 - $108.67 $18,593 - $25,102
231 Added 0.78%
29,993 $3.21 Million
Q3 2020

Oct 19, 2020

SELL
$85.91 - $100.83 $247,248 - $290,188
-2,878 Reduced 8.82%
29,762 $2.61 Million
Q2 2020

Jul 07, 2020

BUY
$73.37 - $98.18 $2.39 Million - $3.2 Million
32,640 New
32,640 $3.21 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Canandaigua National Corp Portfolio

Follow Canandaigua National Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Canandaigua National Corp, based on Form 13F filings with the SEC.

News

Stay updated on Canandaigua National Corp with notifications on news.